Michael Kent Bates

US Patent:

8349574, Jan 8, 2013

Filed:

Jan 15, 2010

Appl. No.:

12/688798

Inventors:

Michael Bates - San Carlos CA, US
Ali Mukherjee - Millbrae CA, US
Gordon Parry - Oakland CA, US
Jeff Sperinde - El Granada CA, US
Jennifer W. Cook - San Mateo CA, US
Gundo Diedrich - Potomac MD, US
Laurie Goodman - El Granada CA, US
Stephen J. Williams - San Carlos CA, US

Assignee:

Laboratory Corporation of America Holdings - Burlington NC

International Classification:

G01N 33/574
G01N 33/53
G01N 33/567

US Classification:

435 723, 435 71, 435 72, 435 721

Abstract:

The invention provides methods of measuring and/or quantifying the presence and/or amount of Her-3 and/or Her-3 in a complex in a sample. The invention also provides antibodies specific for Her-3.

US Patent:

20050214750, Sep 29, 2005

Filed:

Feb 4, 2005

Appl. No.:

11/052741

Inventors:

Neil Parkin - Belmont CA, US
Colombe Chappey - San Francisco CA, US
Michael Bates - San Carlos CA, US

International Classification:

C12Q001/70
C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435005000, 435006000, 702019000

Abstract:

This invention relates to methods for predicting replication capacity of a virus based on genotype and identifying targets for antiviral therapy by identifying mutations associated with altered replication capacity. The methods are useful, for example, for identifying previously unknown interactions among viral molecules or between viral molecules and host cell molecules that are essential to viral infection and/or replication. By identifying such interactions, novel targets for antiviral therapy can be identified. In another aspect, the invention provides a method for determining that an HIV has an altered replication capacity. In certain embodiments, the method comprises detecting a mutation in a codon of gag that is selected from the group consisting of 437, 439, 441, 442, 454, 478, 479, and 484. In certain embodiments, the mutation is selected from the group consisting of I437L, P439S, E454V, P478L, and I479K In certain embodiments, the mutation is in a codon of gag that is selected from the group consisting of 418, 456, 456, 453, 418, 483, 481, 465, 429, 484, 481, 483, 484, 465, 454, 442, 479, 418, 479, and 486.

US Patent:

20090191559, Jul 30, 2009

Filed:

Dec 19, 2008

Appl. No.:

12/340436

Inventors:

Weidong Huang - Pleasanton CA, US
Jeff Sperinde - El Granada CA, US
Michael Bates - San Carlos CA, US
Colombe Chappey - San Francisco CA, US

Assignee:

MONOGRAM BIOSCIENCES, INC. - South San Francisco CA

International Classification:

C12Q 1/68
C12Q 1/02
G01N 33/574

US Classification:

435 6, 435 29, 435 723

Abstract:

In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.

US Patent:

20100233732, Sep 16, 2010

Filed:

Jan 15, 2010

Appl. No.:

12/688766

Inventors:

Michael Bates - San Carlos CA, US
Jennifer W. Cook - San Mateo CA, US
Gundo Diedrich - Potomac MD, US
Laurie Goodman - El Granada CA, US
Ali Mukherjee - Millbrae CA, US
Gordon Parry - Oakland CA, US
Jeff Sperinde - El Granada CA, US
Stephen J. Williams - San Carlos CA, US

Assignee:

Laboratory Corporation of America Holdings - Burlington NC

International Classification:

G01N 33/574

US Classification:

435 723

Abstract:

Methods are provided for determining or otherwise assessing the response of a patient to treatment, in particular, to cancer treatment. The methods include the analysis of samples for the presence or the absence of HER2 markers alone or in conjunction with other biomarkers, such as HER3 markers. In certain examples, the probable time to progression can be determined by first determining HER2 positive patients and then further stratifying by using the presence or the absence of a second biomarker (e.g, HER3 markers). In addition, the data can be used to track a patient's response to a treatment regimen, assessing the expected success of treating a patient using a particular regiment, determining the effects of a treatment regiment or for categorizing a patient in order to create a homogenous group for a clinical trial.

US Patent:

20120295259, Nov 22, 2012

Filed:

May 21, 2012

Appl. No.:

13/476735

Inventors:

Weidong Huang - Pleasanton CA, US
Jodi Weidler - Foster City CA, US
Jeff Sperinde - El Granada CA, US
Mojgan Haddad - Orinda CA, US
Michael Bates - San Carlos CA, US

Assignee:

LABORATORY CORPORATION OF AMERICA HOLDINGS - Burlington NC

International Classification:

G01N 33/574
G01N 21/64

US Classification:

435 611, 435 723

Abstract:

The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

US Patent:

20230062274, Mar 2, 2023

Filed:

Jun 30, 2022

Appl. No.:

17/855437

Inventors:

- Burlington NC, US
Jodi Weidler - Foster City CA, US
Jeff Sperinde - El Granada CA, US
Mojgan Haddad - Orinda CA, US
Michael Bates - San Carlos CA, US
John William Winslow - El Granada, IS
Xueguang Jin - Fremont CA, US
Gerald J. Wallweber - Foster City CA, US
Jennifer W. Cook - San Mateo CA, US
Gundo Diedrich - South San Francisco CA, US
Laurie Goodman - El Granada CA, US
Ali Mukherjee - Millbrae CA, US
Gordon Parry - Oakland CA, US
Stephen J. Williams - San Carlos CA, US

Assignee:

Laboratory Corporation of America Holdings - Burlington NC

International Classification:

C07K 16/32
G01N 33/50
G01N 33/68
A61P 35/00
G01N 33/574
G01N 33/74
C12Q 1/6886
A61K 45/06

Abstract:

The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

US Patent:

20190257836, Aug 22, 2019

Filed:

Oct 22, 2018

Appl. No.:

16/166816

Inventors:

- Burlington NC, US
Jodi Weidler - Foster City CA, US
Jeff Sperinde - El Granada CA, US
Mojgan Haddad - Orinda CA, US
Michael Bates - San Carlos CA, US
John William Winslow - El Granada CA, US
Xueguang Jin - Fremont CA, US
Gerald J. Wallweber - Foster City CA, US

Assignee:

Laboratory Corporation of America Holdings - Burlington NC

International Classification:

G01N 33/574

Abstract:

The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.

US Patent:

20190055319, Feb 21, 2019

Filed:

Oct 22, 2018

Appl. No.:

16/166878

Inventors:

- Burlington NC, US
Jodi Weidler - Foster City CA, US
Jeff Sperinde - El Granada CA, US
Mojgan Haddad - Orinda CA, US
Michael Bates - San Carlos CA, US
John William Winslow - El Granada CA, US
Xueguang Jin - Fremont CA, US
Gerald J. Wallweber - Foster City CA, US
Jennifer W. Cook - San Mateo CA, US
Gundo Diedrich - South San Francisco CA, US
Laurie Goodman - El Granada CA, US
Ali Mukherjee - Millbrae CA, US
Gordon Parry - Oakland CA, US
Stephen J. Williams - San Carlos CA, US

Assignee:

Laboratory Corporation of America Holdings - Burlington NC

International Classification:

C07K 16/32
G01N 33/50
G01N 33/68
A61P 35/00
C12Q 1/6886
G01N 33/574
G01N 33/74

Abstract:

The present invention relates generally to methods of accurately quantifying HER2 and/or p95 expression in subjects with a HER2 positive cancer and indicating the risk of brain relapse in such patients.